Lv11
50 积分 2025-05-25 加入
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease
2小时前
待确认
Drug targets in prostate cancer: an appetite for KLK2-mediated destruction
17天前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
17天前
已完结
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
1个月前
已完结
The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential
1个月前
已完结
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers
1个月前
已完结
Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor
2个月前
已完结
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
2个月前
已完结
Autocrine‐Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries
2个月前
已完结
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity
2个月前
已完结
皖公网安备34019202002308
